Annual report pursuant to Section 13 and 15(d)

INCOME TAXES

v3.8.0.1
INCOME TAXES
12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block]
10.  INCOME TAXES
 
 
 
2017
 
2016
 
 
 
 
 
 
 
 
 
Tax provision (benefit)
 
 
 
 
 
 
 
Current
 
 
 
 
 
 
 
Federal
 
$
 
$
 
State
 
 
 
 
 
Total current
 
 
 
 
 
 
 
 
 
 
 
 
 
Deferred
 
 
 
 
 
 
 
Federal
 
 
13,626,404
 
 
(4,053,114)
 
State
 
 
1,969,262
 
 
99,883
 
Total deferred
 
 
15,595,666
 
 
(3,953,231)
 
 
 
 
 
 
 
 
 
Change in valuation allowance
 
 
(15,595,666)
 
 
3,953,231
 
Total
 
$
 
$
 
 
Deferred tax assets consisted of the following at December 31:
 
 
 
2017
 
2016
 
 
 
 
 
 
 
 
 
Deferred tax assets
 
 
 
 
 
 
 
Federal net operating loss
 
$
24,353,504
 
$
36,472,996
 
Federal research and development tax credit carryforwards
 
 
4,947,879
 
 
3,808,862
 
State net operating losses and tax credit carryforwards
 
 
1,589,927
 
 
2,628,006
 
Capitalized research and development expenses
 
 
5,772,165
 
 
8,834,640
 
Stock-based compensation expense
 
 
1,445,078
 
 
2,162,703
 
Depreciable assets
 
 
166,793
 
 
 
Other
 
 
121,680
 
 
235,681
 
Total deferred tax assets
 
 
38,397,026
 
 
54,142,888
 
 
 
 
 
 
 
 
 
Deferred tax liabilities
 
 
 
 
 
 
 
Depreciable assets
 
 
 
 
(150,196)
 
Total deferred tax liabilities
 
 
 
 
(150,196)
 
 
 
 
 
 
 
 
 
Net deferred tax assets
 
 
38,397,026
 
 
53,992,692
 
Less– valuation allowance
 
 
(38,397,026)
 
 
(53,992,692)
 
Total deferred tax assets
 
$
 
$
 
  
A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations is as follows:
 
 
 
Year ended December 31,
 
 
 
2017
 
2016
 
Income tax benefit using U.S. federal statutory rate
 
 
34.00
%
 
34.00
%
State income taxes
 
 
(9.58)
%
 
(1.07)
%
Permanent items
 
 
(2.55)
%
 
17.88
%
Federal tax credits
 
 
8.43
%
 
9.55
%
Change in valuation allowance
 
 
115
%
 
(63.97)
%
Federal rate change
 
 
(143.50)
%
 
 
Other
 
 
(1.80)
%
 
3.61
%
Total
 
 
0.00
%
 
0.00
%
 
As of December 31, 2017, the Company had federal and state net operating loss carryforwards (“NOLs”) of approximately $115,969,000 and $15,862,000 respectively, which expire in 2018 through 2037 and in 2028 through 2031, respectively.  In addition, the Company has federal and state research and development and orphan drug credits of approximately $4,948,000 and $759,000, respectively, which expire in 2018 through 2037 and in 2024 through 2032, respectively.  The amount of NOLs and tax credit carryforwards which may be utilized annually in future periods will be limited pursuant to Section 382 of the Internal Revenue Code as a result of substantial changes in the Company’s ownership that have occurred or that may occur in the future.  The Company has not quantified the amount of such limitations.
 
Because of the Company’s continuing losses and uncertainty associated with the utilization of the deferred tax assets in the future, management has provided a full allowance against the net deferred tax asset.
 
The Company did not have unrecognized tax benefits or accrued interest and penalties at any time during the years ended December 31, 2017 or 2016, and does not anticipate having unrecognized tax benefits over the next twelve months.  The Company is subject to audit by the IRS and state taxing authorities for tax periods commencing January 1, 2014. Additionally, the Company may be subject to examination by the IRS for years beginning prior to January 1, 2014 as a result of its NOLs. However, any adjustment related to these periods would be limited to the amount of the NOL generated in the year(s) under examination.
 
On December 22, 2017 The Tax Cuts and Jobs Act (the “Act”) was enacted. The Act significantly revised the U.S. corporate income tax law by lowering the corporate Federal income tax rate from 35% to 21%. As of December 31, 2017, the Company has assessed the effects of the corporate rate reduction on its existing deferred tax balances which resulted in the valuation allowance equal to the effect of the rate reduction on the ending deferred tax asset was also reflected. In addition to the rate reduction, the Act also requires companies with foreign subsidiaries to pay a one-time transition tax on earnings that were previously tax deferred. As of December 31, 2017, the Company does not maintain any foreign subsidiaries and does not have previously deferred foreign earnings subject to the transition tax.